Transforming how diseases are detected and monitored.
Cancer remains one of the most serious health challenges in India. Every year, more than 1.3 million people are newly diagnosed and nearly 850,000 lives are lost to the disease. Most of the cancers are frequently overlooked in their early stages, with many cases progressing to advanced disease before diagnosis. Breast cancer, lung cancer, colorectal cancer, and ovarian cancer together contribute to nearly 50% of cancer-related deaths.
Lung cancer is not only the most commonly diagnosed cancer worldwide but also the leading cause of cancer-related deaths in India. Over 80% of Indian lung cancer patients are diagnosed at a late stage, when treatment options are limited and survival rates are low. Similarly, more than 70% of ovarian cancer cases in India are detected at advanced stages, resulting in poor survival outcomes. Colorectal cancer, while less common than lung or breast cancer, is on the rise in India, and nearly two-thirds of patients are diagnosed only after the disease has progressed, significantly reducing the chances of curative treatment.
These challenges are compounded by gaps in access to early diagnostic tools. In India, there are no reliable point-of-care (POC) tests for these cancers and diagnostics remain expensive, invasive, or clinically limited. Without early detection, opportunities for timely treatment and therapy monitoring are lost.
At BridgeInDx, we are addressing this critical unmet need. We are developing non-invasive, AI-integrated rapid tests that allow for quick detection and ongoing monitoring of cancers, helping patients receive care at the right time. Our solutions are designed for hospitals, primary health centers, diagnostic laboratories, and even at-home use, ensuring accessibility in both urban and rural communities.
BridgeInDx is a healthcare diagnostics company headquartered in Hyderabad, India, dedicated to transforming how diseases are detected and monitored. We believe that the future of healthcare lies in affordable, non-invasive, and intelligent diagnostics.
